Autoantibodies emerge early in the disease process, offering the potential to establish disease-specific signatures that support early detection—even before symptoms appear. These predictive signatures can identify disease states and guide timely intervention.
Autoantibody signatures also play a critical role in precision medicine, helping to match patients with the treatments most likely to benefit them. Companion diagnostics (CDx) based on these signatures ensure that only the right patients receive targeted therapies, enhancing treatment safety and effectiveness.
Our assays, which can analyze multiple autoantibody targets simultaneously, accelerate the discovery and validation of high-value predictive signatures—bringing us closer to earlier diagnosis and more personalized patient care.
